DTHR - Dthera Sciences

Other OTC - Other OTC Delayed Price. Currency in USD
2.3000
-0.7000 (-23.33%)
At close: 3:24PM EDT
Stock chart is not supported by your current browser
Previous Close3.0000
Open2.5000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.2300 - 2.5000
52 Week Range0.3000 - 9.2500
Volume2,750
Avg. Volume641
Market Cap6.14M
Beta (3Y Monthly)11.05
PE Ratio (TTM)N/A
EPS (TTM)-1.4820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE23 days ago

    Dthera Sciences Announces Pursuit of Strategic Transaction

    SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Dthera™ Sciences (DTHR) a leading digital therapeutic company specializing in neurodegenerative diseases, today announced that its Board of Directors has initiated a process to pursue a range of potential strategic transactions to enable the Company to bring its development-stage Alzheimer's product, DTHR-ALZ, to market more rapidly.

  • ACCESSWIRE2 months ago

    Dthera Sciences Announces Exclusivity Period and Option Agreement for its Digital Therapeutic in the Japanese Market

    SAN DIEGO, CA / ACCESSWIRE / February 25, 2019 / Dthera™ Sciences (DTHR), a leading digital therapeutic company specialized in neurodegenerative diseases, is pleased to announce that it has entered into an exclusivity agreement with a company headquartered in Japan for development and commercialization rights to Dthera's lead product, DTHR-ALZ. The exclusivity agreement provides exclusive rights to the Japanese partner to perform feasibility studies in Japan and to negotiate a licensing agreement or other transaction for the Japanese market during the agreed term.

  • ACCESSWIRE2 months ago

    Dthera Sciences SVP to Speak on Keynote Panel about Digital Therapeutics in Biopharma at OCT West Coast Conference

    SAN DIEGO, CA / ACCESSWIRE / February 13, 2019 / DtheraTM Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Martin Culjat, Ph.D., Senior Vice President of Scientific & Regulatory Affairs, will speak on the opening keynote panel at Outsourcing in Clinical Trials West Coast (OCT West Coast). The keynote panel is entitled ''Taking Stock of New Players Entering the Healthcare Space: An Opportunity or Threat for Traditional Biopharma?'' and will focus on the potential impact that non-traditional players such as digital therapeutics can have in the biopharma sector. Dr. Culjat is also giving a separate presentation at the conference, entitled ''Overcoming regulatory challenges in digital therapeutic development.'' This presentation will focus on regulatory considerations in the clinical development of digital therapeutics as well as similarities and differences between clinical trials in digital therapeutics and traditional drug trials.

  • ACCESSWIRE3 months ago

    Dthera Sciences CTO to Present on Digital Therapeutics for NASA at MIT Workshop on Cognitive Performance in Space

    SAN DIEGO, CA / ACCESSWIRE / February 6, 2019 / DtheraTM Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Dave Keene, Co-Founder and Chief Technology Officer, will be speaking at a NASA-sponsored workshop on cutting edge and emerging technologies for space health. The Workshop will be hosted by the Translational Research Institute for Space Health (TRISH) and will be held at MIT Media Lab in Cambridge, MA from February 6-7, 2019. The workshop is intended to bring together ideas and evidence that are expected to make major contributions to the understandings of how the environment of a spacecraft can be enriched to maximize human health - specifically behavioral and cognitive health.

  • ACCESSWIRE4 months ago

    Dthera Sciences Chief Technology Officer to Speak at CES Digital Health Summit

    SAN DIEGO, CA / ACCESSWIRE / January 7, 2019 / Dthera™ Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Dave Keene, Co-Founder and Chief Technology Officer will be speaking at CES, Digital Health Summit, A Brain and Mental Health Crisis Intervention. CES 2019, is January 8-11, 2019 in Las Vegas. Mr. Keene will be discussing the future of digital therapeutics and specifically treatments for those suffering from Alzheimer's and other dementias.

  • ACCESSWIRE4 months ago

    FDA Supports De Novo Pathway for Dthera Sciences’ Breakthrough Alzheimer’s Device

    SAN DIEGO, CA / ACCESSWIRE / December 13, 2018 / Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, announced today that the U.S. Food and Drug Administration (FDA) has informed Dthera that it believes that a De Novo submission is the most appropriate regulatory pathway for DTHR-ALZ, as Dthera had proposed. DTHR-ALZ is a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease. If granted clearance by the FDA, DTHR-ALZ would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer's disease.

  • ACCESSWIRE4 months ago

    Dthera Sciences to Provide Corporate Update at the Digital Medicine and Medtech Showcase

    SAN DIEGO, CA / ACCESSWIRE / December 11, 2018 / Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, will be presenting at the Digital Medicine and MedTech Showcase 2019 on Tuesday, January 8 at 10:30am PST in San Francisco. Edward Cox, CEO of Dthera Sciences, will provide an update on the company's upcoming milestones and strategy. Dthera is developing DTHR-ALZ, a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease.

  • ACCESSWIRE6 months ago

    Dthera Sciences Appoints Dr. Amir Kalali to Board of Directors

    SAN DIEGO, CA / ACCESSWIRE / October 30, 2018 / Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce the appointment of Amir Kalali, M.D. to its Board of Directors. Dr. Kalali will also be Chairman of Dthera's Scientific Advisory Board. Dr. Kalali is recognized globally as a leading innovator at the intersection of life sciences and technology, advising companies on building the future of their business at the board level or as a strategic advisor.

  • ACCESSWIRE7 months ago

    Digital Therapeutic Leaders Dthera Sciences' and Click Therapeutics' Executives to act as Co-Chairs of Second Digital Therapeutics Summit

    SAN DIEGO, CA / ACCESSWIRE / September 25, 2018 / Dthera™ Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that its CEO, Edward Cox, has been ...

  • ACCESSWIRE7 months ago

    Dthera Sciences Announces Reverse Split

    SAN DIEGO, CA / ACCESSWIRE / September 25, 2018 / Dthera™ Sciences (DTHR) (DTHRD), the leading digital therapeutic company focusing on the elderly, announced today that the Company's stockholders approved an amendment to the Company's Articles of Incorporation to effectuate a reverse stock split of the Company's outstanding common stock. Effective September 25, 2018, a 1-for-20 reverse stock split of the Company's common stock will take effect, with shares trading on a post-split adjusted basis on September 25, 2018. "This reverse split is a key step in executing our long-term plan of achieving a National Exchange listing, such as the NASDAQ, in 2018," said Dthera CEO Edward Cox.

  • ACCESSWIRE8 months ago

    Dthera Sciences to Present at the 7th Annual Liolios Gateway Conference on September 5, 2018

    SAN DIEGO, CA / ACCESSWIRE / August 30, 2018 / Dthera™ Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, has been invited to present at the 7th Annual Liolios Gateway ...

  • ACCESSWIRE8 months ago

    Dthera Sciences Receives FDA Breakthrough Device Designation For Its Alzheimer's Focused Development-Stage Product ''DTHR-ALZ''

    SAN DIEGO, CA / ACCESSWIRE / August 23, 2018 / Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ. DTHR-ALZ, if granted approval, would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer's disease. The proposed indication for use states that "DTHR-ALZ is intended to mitigate the symptoms of agitation and depression associated with major neurocognitive disorder of the Alzheimer's type." To the Company's knowledge, Dthera Sciences is only the second digital therapeutics company to obtain Breakthrough Device designation from the FDA.

  • Dthera Sciences Receives FDA Breakthrough Device Designation For Its Alzheimer's Focused Development-Stage Product "DTHR-ALZ"
    PR Newswire8 months ago

    Dthera Sciences Receives FDA Breakthrough Device Designation For Its Alzheimer's Focused Development-Stage Product "DTHR-ALZ"

    SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ. DTHR-ALZ, if granted approval, would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer's disease. The proposed indication for use states that "DTHR-ALZ is intended to mitigate the symptoms of agitation and depression associated with major neurocognitive disorder of the Alzheimer's type." To the Company's knowledge, Dthera Sciences is only the second digital therapeutics company to obtain Breakthrough Device designation from the FDA.

  • ACCESSWIRE9 months ago

    Dthera Sciences Launches ReminX - The First Digital Therapeutic Consumer Health Product for Individuals with Alzheimer's Disease and Social Isolation

    SAN DIEGO, CA / ACCESSWIRE / August 1, 2018 / Dthera™ Sciences (DTHR), a San Diego-based digital therapeutics company developing innovative quality of life therapies for the elderly, announced the launch of ReminX™, an artificial-intelligence-powered consumer health product designed to digitally deliver Reminiscence Therapy to individuals suffering from Alzheimer's and other dementias, as well as from social isolation. According to the Alzheimer's Association, Alzheimer's disease is the only top 10 cause of death that cannot be prevented, cured, or slowed. Additionally, nearly half of elderly Americans are estimated to be impacted by social isolation, and AARP estimates the health effects of social isolation to be equivalent to smoking 15 cigarettes per day.

  • ACCESSWIRE9 months ago

    Dthera Sciences Closes Private Placement Ahead of Commercial Launch

    SAN DIEGO, CA / ACCESSWIRE / July 23, 2018 / Dthera Sciences (DTHR), a digital therapeutics company developing innovative quality of life therapies for the elderly, has received the final tranche of investment into its previously announced pre-launch equity private placement. "We are pleased to have closed our Pre-Launch Financing Round ahead the upcoming launch of ReminX," said Edward Cox, CEO of Dthera Sciences. "The timing and terms of this financing provide strong affirmation by investors regarding the company's inherent value.

  • ACCESSWIRE9 months ago

    Dthera Sciences Supported Multiple Alzheimer's Charitable Events in First Half of 2018

    SAN DIEGO, CA / ACCESSWIRE / July 19, 2018 / Dthera™ Sciences (DTHR), a digital therapeutics company focused on developing innovative digital quality of life therapies for the elderly and those suffering from cognitive decline, announced today that it raised funding for three Alzheimer's events in the first half of 2018. The charitable efforts were part of the pre-launch activities for ReminX™, an artificial-intelligence-powered consumer health product designed to deliver reminiscence therapy digitally. The events included "The Longest Day" campaign for the San Diego/Imperial Chapter of the Alzheimer's Association, Keep Memory Alive's "Power of Love" gala, and the Lou Blaney Memorial Event.

  • ACCESSWIRE9 months ago

    Dthera Sciences' ReminX Product Featured on San Diego News

    SAN DIEGO CA / ACCESSWIRE / July 16, 2018 / Dthera™ Sciences (OTCQB: DTHR) CEO Edward Cox and CTO David Keene appeared on KUSI News San Diego to discuss ReminX™, ahead of its imminent launch. A video of ...

  • ACCESSWIRElast year

    ReminX Dementia Paper Accepted at International Academic Conference

    SAN DIEGO, CA / ACCESSWIRE / May 3, 2018 / Dthera™ Sciences (DTHR), a digital therapeutics company developing innovative quality of life therapies for the elderly and those suffering from cognitive decline, announced that the paper, "Evaluation of ReminX as a Behavioral Intervention for Mild to Moderate Dementia," has been accepted for presentation at the 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC'18), in Honolulu, from July 17-21, 2018 (https://embc.embs.org/2018/). The paper describes the design and clinical pilot testing of ReminX™, an artificial-intelligence-powered consumer health computer tablet designed to deliver personalized reminiscence therapy digitally to individuals suffering from dementia and seniors experiencing social isolation.